Company Overview
Prime Medicine, Inc. operates within the healthcare sector specifically as a biotechnology firm focused on delivering genetic medicines to address a spectrum of diseases through the deployment of gene editing technology in the United States. The company's strategic focus is heavily concentrated on its lead therapeutic product candidate, PM359, which is currently undergoing Phase 1/2 clinical trials for the treatment of Chronic Granulomatous Disease. As of the latest data, the company maintains a market capitalization of $669.85M and employs a workforce of 146 individuals to execute its research and development objectives. When analyzing the relationship between the market cap of $669.85M and the trailing twelve-month revenue of $4.63M, these figures indicate that the company possesses a high valuation relative to its current financial output, a characteristic often observed in early-stage biotechnology entities where future potential is priced into the equity rather than current cash flows.
Financial Health
The financial statements for Prime Medicine, Inc. show a trailing twelve-month revenue of $4.63M alongside a net income of $-201,142,000 and an EBITDA of $-201,028,992. The substantial gap between the modest revenue of $4.63M and the negative net income reveals a cost structure dominated by high fixed costs, primarily associated with clinical trial expenses and research operations that exceed current sales generation. The company reports a free cash flow of $-85,365,752, which indicates that the business is currently burning cash to fund its development pipeline rather than generating liquidity from operations. Regarding profitability metrics, the gross margin stands at 0.0%, the operating margin is -5800.5%, and the profit margin is 0.0%; these levels reflect the early commercialization phase where revenue recognition does not yet cover the significant operating expenditures required to bring gene therapies to market. In terms of solvency, the company holds $177.68M in cash against $116.43M in debt, resulting in a debt-to-equity ratio of 96.33, which suggests a levered balance sheet where liabilities are nearly equal to equity. Despite the leverage, the current ratio of 4.84 demonstrates a robust ability to meet short-term obligations with available assets. Finally, the return on equity is -146.8% and the return on assets is -40.7%, metrics that reveal that management is currently utilizing shareholder capital to generate losses rather than positive returns, a common dynamic for biotech firms in the clinical trial stage.
Valuation Assessment
Valuation metrics for Prime Medicine, Inc. present a distinct picture when comparing the trailing P/E ratio, which is N/A due to losses, against a forward P/E of -4.57; this divergence implies that the market is pricing in a future trajectory where earnings are expected to turn positive, although the negative forward multiple currently suggests continued projected losses. The price-to-book ratio is recorded at 5.43, indicating that the market values the company's equity at a significant premium over its net asset book value, likely reflecting the intangible value of the intellectual property and clinical pipeline. Alternative valuation measures such as the price-to-sales ratio of 144.61 and an EV/EBITDA of -2.80 further highlight that the stock is valued based on revenue potential and market expectations rather than current profitability or earnings multiples. The stock has traded within a range defined by a 52-week high of $6.94 and a 52-week low of $1.11, meaning the current price position relative to this historical volatility band must be interpreted through the lens of the company's binary development risks rather than standard mean-reversion patterns. The beta value of 2.58 indicates that the stock's price volatility is substantially higher than that of the broader market, suggesting that investor sentiment regarding the success of the PM359 clinical trials or other pipeline assets will drive price swings with amplified intensity compared to large-cap pharmaceutical peers.
Growth & Income
The growth profile of Prime Medicine, Inc. is characterized by a revenue growth rate of -61.6% year-over-year, while earnings growth is marked as N/A due to the absence of positive earnings; this dynamic implies that the company is not currently scaling revenue in a way that covers its massive burn rate, and the lack of earnings growth simply reflects the fundamental inability to generate profit at this stage of development. As the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows the standard model for biotechnology firms where all available capital is reinvested directly into research, clinical trials, and operational expansion rather than being distributed to shareholders. The overall growth and income profile for Prime Medicine, Inc. is therefore defined by negative revenue momentum and zero income distribution, relying entirely on the successful execution of its clinical program to alter the financial trajectory in future periods.